← All verdicts
Verdict

Data Unavailable

Every analyzed stock in Data Unavailable — 2,921 companies. Each card shows price, our model's intrinsic value (IV), and how far price sits above or below it. Click any card for the full analysis. This is a research-triage view, not a buy/sell signal.

Educational use only — not investment advice. "Undervalued / fairly valued / overvalued" and every risk score reflect our models vs. price, which can be wrong or based on stale or incomplete data. Always review the company's own financials and SEC filings, and consult a licensed advisor, before acting.
"Data Unavailable" by: Model value (price vs DCF) Owner-earnings return (equity bond)

This lens: price against our probability-weighted DCF value (P/IV). Its own forward record began accruing on 2026-09-10 (daily snapshots); until a year of it exists, the panel below tests the nearest cousin we can measure point-in-time — cheap on book value — and says so.

Market state today: Calm — the S&P 500 closed 2.0% below its 1-year high (as of 2026-09-17). Our rule, the same one used to split every backtest on this site: sell-off = 10% or more below the 1-year high, borderline from 5%, calm otherwise. A further 8.2% fall from here would put us in a sell-off. Since 2006 the market has been in a sell-off 16.6% of the time, across 13 episodes (red bands).
2007200920112013201520172019202120232025
S&P 500 (SPY, adjusted) distance from its trailing 1-year high, weekly. Amber band: borderline (−5% to −10%). Red band: sell-off (below −10%). The dot is today. History to 2026-08-19 from the research database; today from the live feed.
Backtest · point in time · 8,702 entries in the study

Does this screen work? The record for exactly these filters

Screen tested: Proxy: price-to-book ≤ 1.2 (undervalued band has no point-in-time history yet) · bought the day of the annual report, held 12 months
Probable Buy every company that met this screen on the day it filed its annual report, hold 12 months: on average it beat the S&P 500 by +12.6 pts (1,427 entries, 311 companies, very unlikely to be luck). 50% of entries beat the S&P; 25% beat it by 30 points or more; 30% trailed it by 20 points or more. Owning everything instead averaged +1.7 pts, so the screen's edge is +10.9 pts.
+12.6 ptsvs S&P, average
50%beat the S&P
25%up 30+ pts vs S&P
30%down 20+ pts vs S&P
+14.0 ptsvs small caps, 12 mo
−15.1 pts 2019worst year to buy ?
6.1luck check ?
Does the holding period matter?3 mo: +2.3 pts 49% beat6 mo: +4.6 pts 49% beat12 mo: +12.6 pts 50% beat24 mo: +21.8 pts 46% beat3 yr, per yr: +1.3 pts 40% beat
Market state at entryCompany-yearsvs S&P 12 movs small caps
Calm ◀ today1,245+7.9 pts t 4.6+10.1 pts
Sell-off (S&P ≥10% off high)182+44.5 pts t 4.0+40.7 pts
Sector (SEC group)nvs S&P 12 mo3 yrs / yr
Industrials & manufacturing466+13.0 pts t 4.0−2.2 pts
Energy126+7.4 pts t 1.2−7.8 pts
Other115+8.4 pts t 1.8+3.8 pts
Tech hardware & semis113+10.9 pts t 1.6+2.3 pts
Services96+11.9 pts t 2.7+12.2 pts
Retail & consumer87+17.2 pts t 2.1+10.2 pts
Finance & real estate72−1.7 pts t -0.5−2.4 pts
Utilities65+5.6 pts t 0.6−1.2 pts
Construction53+13.2 pts t 1.7−2.4 pts
Biotech & pharma44+47.1 pts t 1.6+10.0 pts
Telecom & media43+14.0 pts t 0.7−6.3 pts
Software & IT services35+39.9 pts t 1.8+1.2 pts

Holds up out of sample? Before 2018: +10.7 pts (n 629, t 6.0). From 2018: +14.0 pts (n 798, t 4.1). Same sign in both halves.

Year2010201120122013201420152016201720182019202020212022202320242025
vs S&P+13 pts+5 pts+14 pts+18 pts−4 pts−4 pts+22 pts+12 pts−3 pts−15 pts+87 pts+8 pts+17 pts−9 pts−7 pts+15 pts
n254310610178841118178991297276108121115

Read the research behind this screen: Price-to-book still sorts, across all sizes → · Test your own combination in the Screen Lab →

Our model values are recomputed daily but were never stored historically, so this band cannot be backtested honestly yet. Daily snapshots began 2026-09-10; a true record accrues from there. Until then the nearest tested cousin is shown — cheap on book value — and labelled as a proxy. Point-in-time: each entry is one company bought at the first close after its 10-K filing date, using only filings available that day, held 12 months; result = total return minus SPY over the same months (vs IWM for 12 months; 3-yr annualised). Survivorship-tilted universe; no costs; read spreads, not levels. Educational, hypothetical, before costs.

Sort by: A–Z Riskiest Most overvalued Most shorted Buyers' strike Largest
MASK
3 E Network Technology Group Ltd
Valuation N/A
Technology Risk 55 · Elevated
Price$1.23
Model IV—
P/IV—
Market implies +18.8%/yr vs model -6.8% · above model
MASS
908 Devices Inc.
Valuation N/A
Healthcare Risk 44 · Elevated
Price$9.52
Model IV—
P/IV—
Market implies +29.1%/yr vs model +7.4% · above model
MAT
MATTEL INC /DE/
Valuation N/A
Consumer Cyclical Risk 60 · High
Price$13.42
Model IV—
P/IV—
Market implies -4.1%/yr vs model +5.6% · below model
MATH
Metalpha Technology Holding Ltd
Valuation N/A
Financial Services Risk 44 · Elevated
Price$0.88
Model IV—
P/IV—
Market implies +71.6%/yr vs model +15.0% · above model
MAZE
Maze Therapeutics, Inc.
Valuation N/A
Healthcare Risk 42 · Elevated
Price$24.23
Model IV—
P/IV—
Market implies +20.0%/yr vs model +15.0% · above model
MB
MASTERBEEF GROUP
Valuation N/A
Consumer Cyclical Risk 27 · Moderate
Price$4.33
Model IV—
P/IV—
Limited data — see page
MBAI
Check-Cap Ltd
Valuation N/A
Healthcare Risk 37 · Moderate
Price$6.49
Model IV—
P/IV—
Limited data — see page
MBAV
M3-Brigade Acquisition V Corp.
Valuation N/A
Financial Services
Price$10.68
Model IV—
P/IV—
Limited data — see page
MBI
MBIA INC
Valuation N/A
Financial Services Risk 54 · Elevated
Price$4.64
Model IV—
P/IV—
Limited data — see page
MBIO
MUSTANG BIO, INC.
Valuation N/A
Healthcare Risk 27 · Moderate
Price$0.50
Model IV—
P/IV—
Limited data — see page
MBOT
Microbot Medical Inc.
Valuation N/A
Healthcare Risk 42 · Elevated
Price$1.45
Model IV—
P/IV—
Limited data — see page
MBRX
Moleculin Biotech, Inc.
Valuation N/A
Healthcare Risk 30 · Moderate
Price$0.72
Model IV—
P/IV—
Limited data — see page
MBVI
M3-Brigade Acquisition VI Corp.
Valuation N/A
Financial Services
Price$10.24
Model IV—
P/IV—
Limited data — see page
MBX
MBX Biosciences, Inc.
Valuation N/A
Healthcare Risk 30 · Moderate
Price$59.49
Model IV—
P/IV—
Limited data — see page
MC
Moelis & Co
Valuation N/A
Financial Services Risk 42 · Elevated
Price$62.71
Model IV—
P/IV—
Limited data — see page
MCGA
Yorkville Acquisition Corp.
Valuation N/A
Financial Services
Price$10.35
Model IV—
P/IV—
Limited data — see page
MCHP
MICROCHIP TECHNOLOGY INC
Valuation N/A
Technology Risk 50 · Elevated
Price$74.20
Model IV—
P/IV—
Market implies +19.8%/yr vs model -1.7% · above model
MCHX
MARCHEX INC
Valuation N/A
Technology Risk 42 · Elevated
Price$1.23
Model IV—
P/IV—
Limited data — see page
MCI
BARINGS CORPORATE INVESTORS
Valuation N/A
Unknown
Price$19.54
Model IV—
P/IV—
Limited data — see page
MCN
XAI Madison Equity Premium Income Fund
Valuation N/A
Unknown
Price$5.60
Model IV—
P/IV—
Limited data — see page
MCR
MFS CHARTER INCOME TRUST
Valuation N/A
Unknown
Price$5.94
Model IV—
P/IV—
Limited data — see page
MCRB
Seres Therapeutics, Inc.
Valuation N/A
Healthcare Risk 39 · Moderate
Price$4.60
Model IV—
P/IV—
Market implies +82.6%/yr vs model +2.0% · above model
MCRP
Micropolis AI Robotics
Valuation N/A
Consumer Cyclical Risk 31 · Moderate
Price$0.81
Model IV—
P/IV—
Limited data — see page
MCTA
Charming Medical Ltd
Valuation N/A
Healthcare Risk 44 · Elevated
Price$29.36
Model IV—
P/IV—
Limited data — see page
MDA
MDA Space Ltd.
Valuation N/A
Consumer Cyclical
Price$28.85
Model IV—
P/IV—
Limited data — see page
MDBH
MDB Capital Holdings, LLC
Valuation N/A
Financial Services Risk 29 · Moderate
Price$2.55
Model IV—
P/IV—
Limited data — see page
MDCX
Medicus Pharma Ltd.
Valuation N/A
Healthcare Risk 54 · Elevated
Price$0.15
Model IV—
P/IV—
Limited data — see page
MDWD
MediWound Ltd.
Valuation N/A
Healthcare Risk 40 · Elevated
Price$13.47
Model IV—
P/IV—
Limited data — see page
MDXH
MDxHealth SA
Valuation N/A
Healthcare Risk 28 · Moderate
Price$0.70
Model IV—
P/IV—
Limited data — see page
MEGI
NYLI CBRE Global Infrastructure Megatrends Term Fund
Valuation N/A
Unknown
Price$14.57
Model IV—
P/IV—
Limited data — see page
MEHA
Functional Brands Inc.
Valuation N/A
Healthcare Risk 40 · Elevated
Price$0.00
Model IV—
P/IV—
Market implies +0.0%/yr vs model +2.0% · in line
MENS
Jyong Biotech Ltd.
Valuation N/A
Healthcare Risk 42 · Elevated
Price$1.99
Model IV—
P/IV—
Limited data — see page
MEOH
METHANEX CORP
Valuation N/A
Basic Materials Risk 26 · Moderate
Price$62.90
Model IV—
P/IV—
Limited data — see page
MESH
Meshflow Acquisition Corp
Valuation N/A
Financial Services
Price$10.08
Model IV—
P/IV—
Limited data — see page
MESO
MESOBLAST LTD
Valuation N/A
Healthcare Risk 38 · Moderate
Price$15.48
Model IV—
P/IV—
Limited data — see page
METC
Ramaco Resources, Inc.
Valuation N/A
Energy Risk 65 · High
Price$11.19
Model IV—
P/IV—
Limited data — see page
METCB
Ramaco Resources, Inc.
Valuation N/A
Energy Risk 56 · Elevated
Price$5.44
Model IV—
P/IV—
Limited data — see page
METCI
Ramaco Resources, Inc.
Valuation N/A
Energy Risk 54 · Elevated
Price$25.39
Model IV—
P/IV—
Limited data — see page
METCZ
Ramaco Resources, Inc.
Valuation N/A
Energy Risk 65 · High
Price$25.50
Model IV—
P/IV—
Limited data — see page
MEVO
M Evo Global Acquisition Corp II
Valuation N/A
Financial Services
Price$10.02
Model IV—
P/IV—
Limited data — see page
MFC
MANULIFE FINANCIAL CORP
Valuation N/A
Financial Services
Price$43.49
Model IV—
P/IV—
Limited data — see page
MFG
MIZUHO FINANCIAL GROUP INC
Valuation N/A
Financial Services Risk 43 · Elevated
Price$11.45
Model IV—
P/IV—
Limited data — see page
MFI
mF International Ltd
Valuation N/A
Technology Risk 40 · Elevated
Price$9.35
Model IV—
P/IV—
Market implies +67.6%/yr vs model +15.0% · above model
MFIC
MidCap Financial Investment Corp
Valuation N/A
Unknown Risk 69 · High
Price$9.09
Model IV—
P/IV—
Limited data — see page
MFICL
MidCap Financial Investment Corp
Valuation N/A
Unknown Risk 59 · Elevated
Price$25.07
Model IV—
P/IV—
Limited data — see page
MFM
MFS MUNICIPAL INCOME TRUST
Valuation N/A
Unknown
Price$5.18
Model IV—
P/IV—
Limited data — see page
MGF
MFS GOVERNMENT MARKETS INCOME TRUST
Valuation N/A
Unknown
Price$2.77
Model IV—
P/IV—
Limited data — see page
MGR
AFFILIATED MANAGERS GROUP, INC.
Valuation N/A
Financial Services Risk 36 · Moderate
Price$19.55
Model IV—
P/IV—
Market implies -50.0%/yr vs model +3.8% · below model
MGRB
AFFILIATED MANAGERS GROUP, INC.
Valuation N/A
Financial Services Risk 34 · Moderate
Price$16.06
Model IV—
P/IV—
Market implies -50.0%/yr vs model +3.8% · below model
MGRD
AFFILIATED MANAGERS GROUP, INC.
Valuation N/A
Financial Services Risk 44 · Elevated
Price$14.48
Model IV—
P/IV—
Market implies -50.0%/yr vs model +3.8% · below model
MGTX
MeiraGTx Holdings plc
Valuation N/A
Healthcare Risk 31 · Moderate
Price$12.76
Model IV—
P/IV—
Market implies +40.8%/yr vs model +21.2% · above model
MGX
Metagenomi Therapeutics, Inc.
Valuation N/A
Healthcare Risk 37 · Moderate
Price$1.16
Model IV—
P/IV—
Market implies +42.8%/yr vs model +2.0% · above model
MH
McGraw Hill, Inc.
Valuation N/A
Communication Services Risk 51 · Elevated
Price$13.24
Model IV—
P/IV—
Limited data — see page
MHD
BLACKROCK MUNIHOLDINGS FUND, INC.
Valuation N/A
Unknown
Price$11.07
Model IV—
P/IV—
Limited data — see page
MHF
WESTERN ASSET MUNICIPAL HIGH INCOME FUND INC.
Valuation N/A
Unknown
Price$6.53
Model IV—
P/IV—
Limited data — see page
MHLA
Maiden Holdings, Ltd.
Valuation N/A
Financial Services Risk 32 · Moderate
Price$9.60
Model IV—
P/IV—
Limited data — see page
MHNC
Maiden Holdings, Ltd.
Valuation N/A
Financial Services Risk 32 · Moderate
Price$11.14
Model IV—
P/IV—
Limited data — see page
MI
NFT Ltd
Valuation N/A
Financial Services Risk 42 · Elevated
Price$2.05
Model IV—
P/IV—
Market implies +28.3%/yr vs model +15.0% · above model
MICC
Magnum Ice Cream Co N.V.
Valuation N/A
Consumer Defensive Risk 54 · Elevated
Price$19.91
Model IV—
P/IV—
Limited data — see page
MIMI
Mint Inc Ltd
Valuation N/A
Technology Risk 51 · Elevated
Price$0.97
Model IV—
P/IV—
Market implies +42.0%/yr vs model +11.8% · above model